STOCK TITAN

Mobia Medical to Participate in the Piper Sandler 38th Annual Healthcare Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Mobia Medical (Nasdaq: MOBI) management will present at the Piper Sandler 38th Annual Healthcare Conference on December 1, 2026. The presentation in New York is scheduled for 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Management will also host one-on-one investor meetings. A live and archived presentation will be available through the investor section of the company’s website.

Loading...
Loading translation...

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

AUSTIN, Texas, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced that members of management will present and host one-on-one investor meetings at the upcoming Piper Sandler 38th Annual Healthcare Conference in New York. The presentation will take place on Tuesday, December 1, 2026, at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

Event: Piper Sandler 38th Annual Healthcare Conference
Date: Tuesday, December 1, 2026
Time: 5:30 a.m. PT / 8:30 a.m. ET
Webcast: https://event.webcasts.com/starthere.jsp?ei=1783629&tp_key=efbad274e1

A live and archived version of the presentation will be available via the News & Events page of the investor section of Mobia Medical’s website.

About Mobia Medical, Inc. 

Mobia Medical, Inc. is a medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The Company’s Vivistim® Paired VNS™ System is the first and only clinically validated, FDA-approved implantable solution designed to improve upper limb function in chronic ischemic stroke survivors with moderate to severe upper extremity impairments. Therapy with the Vivistim® Paired VNS™ System combines targeted vagus nerve stimulation with functional movement to promote neuroplasticity and drive meaningful improvements in motor function. Mobia Medical is mobilizing patients, providers, and care partners to establish a better way forward in stroke care.  

Investor Relations Contact 

Louisa Smith
Gilmartin Group, LLC 
investors@mobia.com

Media Inquiries Contact

Terri Clevenger
tclevenger@waterhousebrands.com


Keep reading